Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ABBV-903 (Limnetrelvir) in Healthy Volunteers
NCT05691699Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Jan 2023
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of limnetrelvir in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum Observed Plasma Concentration, Time to Maximum Observed Plasma Concentration and 6 more. Started Jan 2023; status: completed.
02
Drugs
limnetrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05691699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05691699.